Bionor Pharma - Minutes from the Annual General Meeting 22 April 2016
(Oslo, Norway, 22 April 2016) The Annual General Meeting of Bionor Pharma ASA (OSE:BIONOR) was completed today.
At the proposal of a group of shareholders, led by Lars H. Høie, a number of the resolutions proposed by the Board were rejected, as per the attached minutes of the AGM. Link
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
David H. Solomon, President and CEO, +45 22 20 63 00, email@example.com
Jørgen Fischer Ravn, VP Investor Relations & Communications,
+45 20 30 39 03, firstname.lastname@example.org
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.